High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. - Concepedia

Concepedia

Publication | Closed Access

High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial.

22

Citations

0

References

2003

Year

J. Sanford Schwartz, Y Richard Wang, John G.F. Cleland, Longlong Gao, M. W. Weiner, Philip A. Poole‐Wilson

Abstract

Cost savings from fewer heart failure hospitalizations offset higher ACE inhibitor costs in the high-dose group. The improved clinical outcomes were achieved without increased treatment costs.